皇家马斯登医院使用持续静脉输注5-氟尿嘧啶治疗小肠腺癌的经验。
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
作者信息
Crawley C, Ross P, Norman A, Hill A, Cunningham D
机构信息
The Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.
出版信息
Br J Cancer. 1998 Aug;78(4):508-10. doi: 10.1038/bjc.1998.523.
Abstract
The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma. Data on all patients with small bowel malignancy who were seen at a single institution over a 5-year period were retrieved from the gastrointestinal unit and hospital databases, and these cases were reviewed. Eight patients with advanced small bowel adenocarcinoma received PVI 5FU-based chemotherapy. The overall response rate in assessable patients was 37.5% (3/8). The median overall survival was 13 months (range 1-28), and progression-free survival was 7.8 months (range 0-15). Overall, the treatment was well tolerated and symptomatic benefit was seen. In conclusion, PVI 5-FU has activity in this disease. This should be assessed either as a single agent or as part of a combination regimen such as epirubicin/cisplatin/PVI FU (ECF) in a multicentre randomized study.
摘要
本研究旨在回顾基于5-氟尿嘧啶持续静脉输注（PVI 5-FU）的化疗在晚期小肠腺癌中的疗效。从胃肠科和医院数据库中检索了在5年期间于单一机构就诊的所有小肠恶性肿瘤患者的数据，并对这些病例进行了回顾。8例晚期小肠腺癌患者接受了基于PVI 5FU的化疗。可评估患者的总缓解率为37.5%（3/8）。中位总生存期为13个月（范围1-28个月），无进展生存期为7.8个月（范围0-15个月）。总体而言，该治疗耐受性良好且有症状改善。总之，PVI 5-FU对该疾病有活性。应在多中心随机研究中评估其作为单一药物或作为表柔比星/顺铂/PVI FU（ECF）等联合方案一部分的疗效。
相似文献
1
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.皇家马斯登医院使用持续静脉输注5-氟尿嘧啶治疗小肠腺癌的经验。
Br J Cancer. 1998 Aug;78(4):508-10. doi: 10.1038/bjc.1998.523.
2
Combination chemotherapy in advanced small bowel adenocarcinoma.晚期小肠腺癌的联合化疗
Oncology. 2005;69(4):290-4. doi: 10.1159/000089678. Epub 2005 Nov 9.
3
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.在晚期食管胃癌中，比较丝裂霉素、顺铂和持续静脉输注氟尿嘧啶（PVI 5-FU）与表柔比星、顺铂和PVI 5-FU的前瞻性随机试验。
J Clin Oncol. 2002 Apr 15;20(8):1996-2004. doi: 10.1200/JCO.2002.08.105.
4
First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.一线持续静脉输注氟尿嘧啶联合顺铂或卡铂治疗晚期结直肠癌。
J Infus Chemother. 1996 Summer;6(3):149-51.
5
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.一项多中心、随机III期试验，比较持续静脉输注（PVI）5-氟尿嘧啶（5-FU）与PVI 5-FU联合丝裂霉素C用于不可切除的食管胃癌患者的疗效。
Ann Oncol. 2002 Oct;13(10):1568-75. doi: 10.1093/annonc/mdf273.
6
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.奥沙利铂与5-氟尿嘧啶持续静脉输注用于晚期或复发的经5-氟尿嘧啶预处理的结直肠癌患者。
Br J Cancer. 2001 Nov 2;85(9):1258-64. doi: 10.1054/bjoc.2001.2036.
7
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.一项多中心随机III期试验，比较持续静脉输注（PVI）氟尿嘧啶（5-FU）与PVI 5-FU联合丝裂霉素治疗不可切除胰腺癌的疗效。
J Clin Oncol. 2002 Jul 15;20(14):3130-6. doi: 10.1200/JCO.2002.09.029.
8
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.表柔比星、顺铂和5-氟尿嘧啶持续静脉输注治疗食管胃腺癌：疗效、毒性、生活质量和生存率。
Cancer. 1996 May 15;77(10):1978-85. doi: 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D.
9
Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.表柔比星、顺铂及延长或短程输注氟尿嘧啶治疗原发部位不明的癌
Med Oncol. 2001;18(1):23-32. doi: 10.1385/MO:18:1:23.
10
Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).肝动脉化疗栓塞联合5-氟尿嘧啶持续静脉滴注治疗肝转移胃肠道恶性肿瘤：普吉特海湾肿瘤协作组II期试验（PSOC 1104）
Clin Cancer Res. 1999 Jan;5(1):95-109.
引用本文的文献
1
Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives.晚期小肠腺癌患者的治疗策略：当前认知与展望
Cancers (Basel). 2022 Feb 23;14(5):1137. doi: 10.3390/cancers14051137.
2
Management of Advanced Small Bowel Cancer.晚期小肠癌的治疗管理。
Curr Treat Options Oncol. 2018 Nov 5;19(12):69. doi: 10.1007/s11864-018-0592-3.
3
The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study.小肠腺癌的特征与预后：一项多中心回顾性观察研究
Br J Cancer. 2017 Nov 21;117(11):1607-1613. doi: 10.1038/bjc.2017.338. Epub 2017 Oct 5.
4
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.一项奥沙利铂联合氟尿嘧啶/亚叶酸钙（mFOLFOX6）治疗日本转移性或不可切除的小肠腺癌患者的 II 期研究。
Int J Clin Oncol. 2017 Oct;22(5):905-912. doi: 10.1007/s10147-017-1138-6. Epub 2017 May 23.
5
A Retrospective Review of Chemotherapy for Patients with Small Bowel Adenocarcinoma in British Columbia.英属哥伦比亚小肠腺癌患者化疗的回顾性研究
J Cancer. 2016 Nov 25;7(15):2290-2295. doi: 10.7150/jca.16606. eCollection 2016.
6
Most small bowel cancers are revealed by a complication.大多数小肠癌是由并发症发现的。
Einstein (Sao Paulo). 2015 Oct-Dec;13(4):500-5. doi: 10.1590/S1679-45082015AO3380. Epub 2015 Dec 11.
7
Adenocarcinoma of Small Bowel.小肠腺癌
Rare Tumors. 2015 Jun 25;7(2):5517. doi: 10.4081/rt.2015.5517. eCollection 2015 May 5.
8
Successful treatment of duodenal adenocarcinoma with multiple liver metastases by S-1 + irinotecan (CPT-11).S-1联合伊立替康（CPT-11）成功治疗多发肝转移十二指肠腺癌
Clin J Gastroenterol. 2009 Aug;2(4):287-290. doi: 10.1007/s12328-009-0099-3. Epub 2009 Jul 1.
9
Recurrence of primary squamous cell carcinoma of the ileum diagnosed by elevation of serum SCC: report of a case.通过血清鳞状细胞癌抗原升高诊断的原发性回肠鳞状细胞癌复发：病例报告
Clin J Gastroenterol. 2012 Jun;5(3):239-44. doi: 10.1007/s12328-012-0309-2. Epub 2012 May 29.
10
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.小肠腺癌（SBA）患者的预后因素及治疗结果：皇家马斯登医院（RMH）的经验
BMC Cancer. 2015 Jan 21;15:15. doi: 10.1186/s12885-015-1014-6.
本文引用的文献
1
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.在晚期食管胃癌中比较表柔比星、顺铂和氟尿嘧啶与氟尿嘧啶、多柔比星和甲氨蝶呤的随机试验。
J Clin Oncol. 1997 Jan;15(1):261-7. doi: 10.1200/JCO.1997.15.1.261.
2
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.表柔比星、顺铂和5-氟尿嘧啶持续静脉输注治疗食管胃腺癌：疗效、毒性、生活质量和生存率。
Cancer. 1996 May 15;77(10):1978-85. doi: 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D.
3
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.胰腺和十二指肠癌的新辅助放化疗。一项II期研究。
Cancer. 1993 Oct 1;72(7):2124-33. doi: 10.1002/1097-0142(19931001)72:7<2124::aid-cncr2820720711>3.0.co;2-c.
4
Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.胰腺和十二指肠腺癌的术前放化疗
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7. doi: 10.1016/0360-3016(94)90531-2.
5
Improving resectability and survival in patients with primary duodenal carcinoma.提高原发性十二指肠癌患者的可切除性及生存率。
Am J Surg. 1993 Dec;166(6):626-30; discussion 630-1. doi: 10.1016/s0002-9610(05)80668-3.
6
Adenocarcinoma of the duodenum: factors influencing survival. French Association for Surgical Research.十二指肠腺癌：影响生存的因素。法国外科研究协会
Br J Surg. 1994 Jan;81(1):83-5. doi: 10.1002/bjs.1800810128.
7
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
8
Adenocarcinoma of the small intestine.小肠腺癌
Am J Surg. 1984 Jan;147(1):66-71. doi: 10.1016/0002-9610(84)90036-9.
9
Chemotherapy for primary adenocarcinoma of the small bowel.小肠原发性腺癌的化疗
Cancer. 1984 Jan 1;53(1):23-5. doi: 10.1002/1097-0142(19840101)53:1<23::aid-cncr2820530106>3.0.co;2-u.
10
Carcinoma of the duodenum: comparison of surgery, radiotherapy, and chemotherapy.十二指肠癌：手术、放疗及化疗的比较
Br J Surg. 1973 Nov;60(11):867-72. doi: 10.1002/bjs.1800601108.
Zotero 插件